RARE insider buying and SEC filings, explained
Ultragenyx Pharmaceutical Inc. · CIK 1515673
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$2.5M
Planned sales (10b5-1)
$1.3M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 15, 2026 | Sale | Howard Horn (CFO) sold 7,066 shares at $15.27 ($108K). Holdings down 7% to 89,229 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 19, 2026, 1:48 PM ET |
| Sep 15, 2026 | Planned (10b5-1) | Theodore Alan Huizenga (SVP, Chief Accounting Officer) sold 1,283 shares at $13.57 ($17K), marked as a 10b5-1 plan trade. Holdings down 2% to 67,863 shares. | SEC filing Filed Sep 15, 2026 |
| Sep 3, 2026 | Sale | Theodore Alan Huizenga (SVP, Chief Accounting Officer) sold 161 shares at $13.99 ($2K). Holdings down <1% to 69,146 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 8, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Karah Herdman Parschauer (EVP and Chief Legal Officer) sold 1,900 shares at $24.92 ($47K), marked as a 10b5-1 plan trade. Holdings down 2% to 92,562 shares. | SEC filing Filed Aug 4, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Howard Horn (CFO) sold 4,696 shares at $24.92 ($117K), marked as a 10b5-1 plan trade. Holdings down 5% to 96,295 shares. | SEC filing Filed Aug 4, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Howard Horn (CFO) sold 4,698 shares at $33.13 ($156K), marked as a 10b5-1 plan trade. Holdings down 4% to 100,991 shares. | SEC filing Filed Jul 6, 2026 |
| Jun 15, 2026 | Sale | Corazon (Corsee) D. Sanders (Director) sold 2,000 shares at $25.05 ($50K). Holdings down 9% to 21,095 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 15, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | Karah Herdman Parschauer (EVP and Chief Legal Officer) sold 1,899 shares at $24.62 ($47K), marked as a 10b5-1 plan trade. Holdings down 2% to 94,462 shares. | SEC filing Filed Jun 15, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Howard Horn (CFO) sold 4,653 shares at $23.77 ($111K), marked as a 10b5-1 plan trade. Holdings down 4% to 105,689 shares. | SEC filing Filed Jun 1, 2026 |
| May 18, 2026 | Planned (10b5-1) | Shehnaaz Suliman (Director) sold 5,740 shares at $25.12 ($144K), marked as a 10b5-1 plan trade. Holdings down 17% to 27,951 shares. | SEC filing Filed May 18, 2026 |
| May 5, 2026 | Sale | Eric Crombez (EVP and Chief Medical Officer) sold 344 shares at $24.96 ($9K). Holdings down <1% to 111,189 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 6, 2026 |
| May 1, 2026 | Planned (10b5-1) | Howard Horn (CFO) sold 4,683 shares at $24.90 ($117K), marked as a 10b5-1 plan trade. Holdings down 4% to 110,342 shares. | SEC filing Filed May 4, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Howard Horn (CFO) sold 4,683 shares at $20.97 ($98K), marked as a 10b5-1 plan trade. Holdings down 6% to 80,351 shares. | SEC filing Filed Apr 2, 2026 |
| Mar 6–10, 2026 | Sale | Karah Herdman Parschauer (EVP and Chief Legal Officer) sold 9,526 shares between Mar 6 and Mar 10 at about $21.87 ($208K). Holdings down 12% to 66,820 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 10, 2026 |
| Mar 2, 2026 | Sale | Theodore Alan Huizenga (SVP, Chief Accounting Officer) sold 1,632 shares at about $22.80 ($37K). Holdings down 3% to 48,670 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | John Richard Pinion (Chief Quality Operations Officer) sold 10,029 shares at about $22.80 ($229K). Holdings down 8% to 110,026 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | Erik Harris (EVP & Chief Commercial Officer) sold 10,539 shares at about $22.80 ($240K). Holdings down 11% to 89,515 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | Emil D. Kakkis (CEO and Director) sold 54,404 shares at about $22.80 ($1.2M). Holdings down 8% to 658,994 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | Karah Herdman Parschauer (EVP and Chief Legal Officer) sold 8,135 shares at about $22.80 ($185K). Holdings down 10% to 76,346 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2–3, 2026 | Planned (10b5-1) | Howard Horn (CFO) sold 10,044 shares between Mar 2 and Mar 3 at about $22.65 ($228K), marked as a 10b5-1 plan trade. Holdings down 11% to 85,034 shares. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | Eric Crombez (EVP and Chief Medical Officer) sold 7,029 shares at about $22.80 ($160K). Holdings down 8% to 76,301 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Howard Horn (CFO) sold 3,061 shares at $23.56 ($72K), marked as a 10b5-1 plan trade. Holdings down 3% to 88,935 shares. | SEC filing Filed Feb 3, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Howard Horn (CFO) sold 3,150 shares at $22.84 ($72K), marked as a 10b5-1 plan trade. Holdings down 3% to 91,996 shares. | SEC filing Filed Jan 5, 2026 |
| Dec 29, 2025 | Sale | Theodore Alan Huizenga (SVP, Chief Accounting Officer) sold 85 shares at $34.38 ($3K). Holdings down <1% to 50,450 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 30, 2025 |
| Dec 10, 2025 | Planned (10b5-1) | Howard Horn (CFO) sold 3,081 shares at $36.38 ($112K), marked as a 10b5-1 plan trade. Holdings down 3% to 95,146 shares. | SEC filing Filed Dec 11, 2025 |
23 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
| Tag | Items | Filed | Source |
|---|---|---|---|
| Restructuring | 8-K Item 2.05 | Nov 3, 2026, 4:07 PM ET | SEC filing |
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 3, 2026, 4:07 PM ET 8-K | Acquisition or disposal completed (Item 2.01) Earnings released (Item 2.02) Restructuring or exit costs (Item 2.05) | Restructuring | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow RARE in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.